CONTINUING MEDICAL EDUCATION INFORMATION
Nonsurgical Treatment Options for Basal Cell Carcinoma—Focus on Advanced Disease
Release Date: December 1, 2013
Last Review: September 16, 2013
Expiration Date: November 30, 2014
Estimated Time to Complete This CME Activity: 0.75 hour
Media/Method of Participation: Journal article, Web based posttest, and evaluation
Hardware/Software Requirements: Any Web browser
*This activity expired for credit on November 30, 2014 and is no longer available for credit
*This activity expired for credit on November 30, 2014 and is no longer available for credit
This activity is sponsored by Global Education Group.
Paradigm Medical Communications is the educational partner.
TARGET AUDIENCE
The educational design of this activity addresses the needs of dermatologists, dermatologic surgeons, medical oncologists, and other healthcare providers involved in the treatment of patients with basal cell carcinoma.
STATEMENT OF NEED
Most cases of basal cell carcinoma (BCC) are cured by surgery, but recurrent or disseminated disease does occur. Nonsurgical options are appropriate for patients with metastatic BCC and those with locally advanced disease considered inoperable or inappropriate for surgery. Recent exploration has begun to elucidate the pathogenesis of BCC, and clinical studies have assessed differences in subtypes and disease course, promoting investigation into a variety of novel nonsurgical therapies.
This activity is designed to provide dermatologists and medical oncologists with information that will allow them to integrate new and emerging nonsurgical agents into daily practice, including how therapies impact cellular pathways leading to basal cell mutagenesis, which patients are most likely to benefit from therapy, and the associated benefits and risks. Collaboration between these two groups in multidisciplinary tumor boards is key to improving diagnosis and outcomes in BCC.
EDUCATIONAL OBJECTIVES
After completing this activity, participants should be better able to:
- Compare the strengths and limitations of nonsurgical BCC options and consider how best to select appropriate patients for these therapies.
FACULTY
| Gary Goldenberg, MD Assistant Professor of Dermatology and Pathology Medical Director of the Dermatology Faculty Practice Icahn School of Medicine at Mount Sinai New York, NY | Omid Hamid, MD Director, Translational Research/Immunotherapy Director of Cutaneous Oncology Chief of Research The Angeles Clinic and Research Institute Los Angeles, CA |
ACCREDITATION and DESIGNATION STATEMENTS
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS FOR OBTAINING CREDIT
To receive a CME certificate of participation, participants must:
- Read the entire publication, including the Continuing Medical Education Information.
- Register or log in at www.paradigmmc.com/bccpub3 and complete and submit the online posttest and evaluation OR complete the posttest/evaluation form at the end of the article and mail or fax it to Paradigm Medical Communications, LLC, 523 Route 303, Orangeburg, NY 10962; fax (845) 398-5153.
- You must answer 66% of the posttest questions correctly to earn credit. Online completion of the posttest allows unlimited opportunities to successfully complete the posttest.
Following online completion of the posttest and evaluation, a certificate of participation will be available for download/printing immediately.Participants who submit a posttest/evaluation form via mail or fax will receive an email with a link to their certificate of participation within 1 to 2 weeks following Paradigm receipt of completed form.
For information about the accreditation of this program, please contact Global at (303) 395-1782 or inquire@globaleducationgroup.com.
There is no fee required for participation in this activity.
DISCLOSURE OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech.
DISCLOSURE OF CONFLICT OF INTEREST
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty, planners, and managers of this activity have the following relationships to report:
| Name | Type of Financial Relationship |
| Gary Goldenberg, MD | Research, speaking, and/or consulting support: AbbVie, Galderma, Genentech, LEO Pharma, Medicis Pharmaceutical Corporation, MELA Sciences, Onset Dermatologics, PharmaDerm, Stiefel |
| Omid Hamid, MD | Research, speaking, and/or consulting support: Bristol-Myers Squibb, Genentech, Merck, Roche |
| Ashley Marostica, RN, MSN | Nothing to disclose |
| Amanda Glazar, PhD | Nothing to disclose |
| Paradigm Medical Communications, LLC staff members | Nothing to disclose |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Paradigm Medical Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.